Sam Klempner, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment strategies for esophageal, GE junction, and gastric cancers.
Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups
Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases
Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Zanzalintinib Combo Improves Survival vs Regorafenib in Metastatic CRC
Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.
Cabozantinib Earns CHMP Recommendation in Pancreatic Neuroendocrine Tumors
Data from the phase 3 CABINET trial support the CHMP’s positive opinion of cabozantinib in well-differentiated extrapancreatic or pancreatic NETs.